A Phase 3b, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia in Subjects Hospitalized for Acute Exacerbation
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 20 Nov 2018
At a glance
- Drugs Aripiprazole lauroxil (Primary) ; Paliperidone (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Alkermes plc
- 08 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 15 Jan 2018 Status changed from not yet recruiting to recruiting.
- 15 Nov 2017 Status changed from planning to not yet recruiting.